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Hepatitis C virus (HCV) has been recognized as a major cause of chronic liver diseases worldwide. It has been suggested that
HCV infects not only hepatocytes but also mononuclear lymphocytes including B cells that express the CD81 molecule, a putative
HCV receptor. HCV infection of B cells is the likely cause of B-cell dysregulation disorders such as mixed cryoglobulinemia,
rheumatoid factor production, and B-cell lymphoproliferative disorders that may evolve into non-Hodgkin’s lymphoma (NHL).
Epidemiological data indicate an association between HCV chronic infection and the occurrence of B-cell NHL, suggesting that
chronic HCV infection is associated at least in part with B-cell lymphomagenesis. In this paper, we aim to provide an overview of
recent literature, including our own, to elucidate a possible role of HCV chronic infection in B-cell lymphomagenesis.
1.Introduction
Hepatitis C virus (HCV) is an enveloped positive-strand
RNA virus that belongs to the Flaviviridae family [1]. HCV
infectionisaworldwideproblemaﬀectingnearly200million
people [2] and causes prolonged and persistent diseases in
virus carriers, often leading to chronic hepatitis, cirrhosis,
and hepatocellular carcinoma [3]. Although the liver is
considered to be the primary target of HCV infection, extra-
hepatic manifestations, such as mixed cryoglobulinemia,
which is a systemic immune complex-mediated disorder
characterized by B-cell proliferation that may evolve into
overt B-cell non-Hodgkin’s lymphoma (B-NHL), are often
recognized among patients persistently infected with HCV
[4, 5]. In fact, epidemiological evidence strongly suggests a
close link between chronic HCV infection and B-NHL [6, 7].
The pathogenic role of HCV in B-cell disorders has been
suggested in reports wherein a clinical resolution of the B-
cell dysfunctions, stated above, was observed after successful
anti-HCVtreatmentusinginterferon(IFN)[8–10].Basedon
suchevidences,apossibleroleofBcellsinHCVpathogenesis
has been postulated but not yet conclusively demonstrated.
The objective of this paper is to summarize recent liter-
ature focused on the possible involvement of HCV infection
in B-cell lymphomagenesis, which could oﬀer new insights
into the role of B cells in the pathogenesis of HCV infection.
2.DoesHCVInfectandReplicate
in Peripheral B Cellsof Chronic
HepatitisC(CHC)Patients?
HCV, as the name indicates, has been regarded as a hepa-
totropic virus. However, the possibility that HCV infects
cells other than hepatocytes cannot be excluded. In the early
1990s, the existence of HCV RNA was demonstrated by PCR
in not only serum/plasma [11] and liver tissues [12] but also
in peripheral blood mononuclear cells (PBMCs) of patients
infected with HCV [13, 14]. Muller et al. ﬁrst reported in
1993thatHCVRNAcouldbefoundinBcells[15].Theypre-
dictedthatPBMC,particularlyBcells,couldbesitesforHCV
replication and may serve as reservoirs of HCV infection.
Moldvayetal.demonstratedthatnegative-strandHCVRNA,
a replicative intermediate of HCV, was observed in PBMC of2 Advances in Hematology
patients with CHC (6 of 11) by in situ hybridization [16].
Muratori et al. reported negative-strand HCV RNA within
PBMC detected by ﬂuorescein-tagged in situ RT-PCR (12
of 14 patients with CHC) [17]. Further evidence suggested
that HCV replicates in B cells. For example, Morsia et al.
demonstrated the replication of HCV in CD19+ Bc e l l sb y
detectingthenegative-strandRNAalthoughtheirsamplesize
was very small (1 of 3 patients with CHC was positive) [18].
Around the same time, Pileri et al. demonstrated that the
HCV envelope protein E2 binds the CD81 molecule that is
expressed on not only hepatocytes but also various cell types
including B cells [19]. This ﬁnding thus provided a rationale
for the notion that HCV infects and replicates in B cells.
Several years later, Gong et al. conﬁrmed the existence of
negative-strand HCV RNA in PBMC of patients with CHC
(14 of 35) [20]. Some argued that the negative-strand HCV
RNA in PBMC may be due to mere contamination or passive
absorption by circulating HCV in peripheral blood. They
successfully excluded this possibility by demonstrating the
expression of HCV-encoding protein, NS5, which indicates
that HCV not only replicates but also produces HCV protein
inPBMC.Theirresultsareinagreementwithanearlierstudy
bySansonno etal.inwhichHCVcoreandNS3proteinswere
detected in PMBC of patients with CHC [21].
Occult HCV infection is characterized by the presence of
HCV RNA in the liver and the absence of both HCV RNA
and anti-HCV antibodies in serum. Castillo et al. detected
HCV RNA in PBMC of 40 of 57 (70%) patients with occult
HCV infection [22]. In a subsequent report, they conﬁrmed
thereplicationofHCVinPBMCofpatientswithoccultHCV
infection by detecting both positive and negative strands
of HCV RNA using a strand-speciﬁc RT-PCR and in situ
hybridization techniques [23]. Meanwhile, Januszkiewicz-
Lewandowska et al. demonstrated the presence of HCV RNA
in PBMC of patients who underwent antiviral chemotherapy
and therefore were HCV-serum negative [24]. Collectively,
these ﬁndings not only favor the notion that PBMC,
particularly B cells (discussed later), infected with HCV can
serve as reservoirs for persistent HCV infection but are also
an alert that PBMC of patients with CHC, including patients
with occult CHC, could be potentially infectious even when
HCV RNA is negative in their sera. There has been a debate
over which cell population in PBMC is the main target for
HCV infection. An array of evidence suggests that HCV
replicatesinvariouscelltypesofPBMC,includingperipheral
dendritic cells, monocytes, and macrophages [25–27]. A
recentstudybyKondoetal.demonstratedthatlymphotropic
HCV (SB strain) could infect not only established T-cell
lines and B-cell lines but also primary na¨ ıve CD4+ T cells,
suggesting that HCV replication in such T cells suppressed
their proliferation and development in Th1 commitment
[28]. Under these circumstances, a number of reports have
indicated that HCV infects CD81-positive lymphocytes,
preferentially B cells [18, 29–31]. Our recent study also
clearly demonstrated that HCV RNA and HCV core and
NS3 proteins are detected in CD19+ but not in CD19−
PBMC [32]. Furthermore, Inokuchi et al. conﬁrmed that
negative-strand HCV RNA, regarded as a marker of viral
replication,wasdetectedinBcellsofpatientswithCHC[33].
Considering this evidence, it can be concluded that HCV
infects and replicates in PBMC, particularly in the CD19+ B-
cell subset, of patients with CHC. An intriguing question has
emerged as to whether diﬀerent HCV variants or B-tropic
HCV cause HCV infection in the CD19+ B cells of patients
with CHC or not. When cDNA sequences derived from RNA
isolatedfromplasmaandCD19+ Bcellsofrandomlyselected
patients with CHC were compared, limited variations were
found in the internal ribosome entry site (IRES) region (our
unpublished data). However, as predicted by a computer
program named mfold, these nucleotide substitutions did
not aﬀect RNA secondary structure or thermodynamic
stability of IRES region [34]. Furthermore, the amino acid
sequences in the hypervariable region 1 (HVR1), which
directly reﬂect clonal variations of HCV, did not show
any distinct diﬀerences between plasma and CD19+ Bc e l l s
of patients with CHC. These results indicate that HCV
RNA isolated from CHC B cells is indistinguishable from
RNA isolated from plasma of the same patient with CHC
(our unpublished data). Sequence polymorphisms located at
IRES and HVR1 of E2 were observed in lymphoid cells of
individuals with persistent HCV infection, strongly favoring
the concept of HCV lymphotropism. Recently, HCV variants
observed in B cells showed poor translational activity in
hepatocytes but not in B-cell lines, indicating that adaptive
mutations had occurred in B cells [35]. However, our
results do not support the concept of lymphotropism or
B-tropism of HCV in patients with CHC [30] but instead
are in good agreement with studies by Muller et al. in
which the PCR products obtained from serum and PBMC
specimens of an HCV-positive individual were found to have
nearly identical sequences [15]. Although the number of
clones analyzed was limited, our conclusion that HCV RNA
isolated from CD19+ B cells is indistinguishable from RNA
isolated from the plasma of the same patient with CHC is
inconsistentwiththeconceptofB-tropicHCVRNA.Further
investigation involving a large number of HCV patients
would be necessary to support this conclusion.
Overall, the data accumulated to date strongly suggest
that HCV infects and replicates in the peripheral B cells
of patients with CHC. However, currently it is not known
whether a novel HCV strain, B-tropic HCV RNA, preferen-
tially infects peripheral B cells or not. The role of B cells in
the pathogenesis of HCV infection is examined in the next
section.
3. Peripheral B Cells May Serve as Reservoirs
for Persistent Infection of HCV
As described in the previous section, evidence indicates
that peripheral B cells in patients with CHC were infected
with HCV and thus may serve as HCV reservoirs. This
evidence posed a logical question as to how HCV evades the
innate antiviral immune responses in B cells. However, this
important issue has so far not been formally investigated.
Sensing mechanisms for invading viruses in host
immune cells consist of toll-like-receptor (TLR-) medi-
ated [36] as well as retinoic-acid-inducible-gene-I-(RIG-
I-) mediated [37] pathways. Both pathways culminate inAdvances in Hematology 3
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Figure 1: Impaired innate antiviral immunity in B cells of patients
with chronic hepatitis C.
the translocation of IFN regulatory factor-3 (IRF-3) to the
nucleus to transcribe the IFN-β gene. Type-I IFN, for exam-
ple,IFN-β,playsacriticalroleintheinnateantiviralimmune
response [38, 39]. In our recent study, it was found that
the expression levels of RIG-I and its adaptor molecule, IFN
promoter-stimulator 1 (IPS-1), were substantially enhanced
in CHC B cells. However, dimerization and the subsequent
nuclear translocation of IRF-3 were almost undetectable in
CHC B cells. It has been demonstrated that TANK-binding
kinase-1 (TBK1) and IκB kinase-ε (IKKε) are essential
for the phosphorylation of IRF-3 [40]. The constitutive
expression levels of both kinases were found to be markedly
enhanced in CHC B cells. However, the reduced expression
of TBK1 stabilizers, including Hsp90 [41] and DDX3X [42],
and the enhanced expression of the IKK suppressor SIKE
[43], were observed in CHC B cells, suggesting that IRF-3
phosphorylationwasdownregulated.Hence,transcriptionof
the IFN-β gene was not augmented. These results strongly
suggest that HCV infection circumvents innate antiviral
immune responses, that is, type I IFN production in B cells,
and (Figure 1) thus, takes advantage of B cells for persistent
infection.
It can be assumed that, among B-cell subsets, memory
B cells are the main reservoirs of HCV infection primarily
because of their long lifespans. Supporting this notion, our
recent study indicated that CD19+ CD27+ cells (memory
B cells [44]) are recruited to the liver of patients with
CHC through the interaction between CXCR3 expressed
on CD19+ CD27+ cells and IP-10 (IFN-γ-inducing protein
10kD) produced in the liver [45]. This strategy would be
beneﬁcial for HCV in securing sites for long-lasting infec-
tion. HCV infection of hepatocytes has long been considered
an a priori assumption. However, this assumption does not
necessarily mean that hepatocytes are the exclusive target of
HCV infection. HCV may search for reservoir sites in other
cellular compartments if the liver becomes unsuitable for
replication, perhaps due to cellular destruction caused by
the host immune response and/or by the development of
conditions such as cirrhosis and hepatocellular carcinoma.
Lymphoid reservoirs of HCV infection could play a
role in viral persistence [29, 46–48]. Several maneuvers
are employed for persistent infection of HCV [49]. Viral
modulation is an eﬀective strategy to escape host immune
responses [50]. Another strategy is the suppression of
the innate immunity of host by viral components. These
components include HCV E2 protein, which acts as a decoy
target of protein kinase R (PKR) [51]; HCV NS3/4A protein,
which cleaves the adaptor molecules TRIF and IPS-1 and
thereby blocks TLR3 and RIG-I signaling, respectively [52,
53]; HCV NS5A protein, which inhibits IFN-stimulated
genes expression [54] and PKR function [55]; HCV core
protein, which interferes with JAK/STAT signaling [56, 57].
Regardless of the mechanisms, the infection and replication
of HCV in peripheral B cells should be considered barriers to
the treatment of patients with CHC with antiviral regimens.
Based on the notion that peripheral B cells serve as reser-
voirs for persistent HCV infection and from a therapeutic
perspective, it may be beneﬁcial to eliminate peripheral B
cells in patients with CHC by the administration of anti-B-
cell antibodies, such as rituximab, along with combination
therapy with peginterferon and ribavirin to eliminate circu-
lating HCV in the blood, leading to a synergistic eﬀect on
HCV clearance in patients with CHC.
4. HCVInfection andB-Cell Lymphomagenesis
The striking association between HCV infection and type II
mixed cryoglobulinemia (MC) has been well documented
[4, 58, 59]. MC is a benign lymphoproliferative disorder
and is regarded as a variant of low-grade B-NHL. Therefore,
lymphotropism of HCV suggests that HCV could play a
pathogenic role in the clonal proliferation of B cells [60, 61].
Because HCV RNA genomic sequences are not able to
integrate into the host genome, indirect mechanisms of
malignant transformation should be considered. In this
regard, the persistent stimulation of B cells by viral antigens
and/or the enhanced expression of lymphomagenesis-related
genes could be responsible for leading to polyclonal and
later to monoclonal expansion of B cells. Furthermore, the
occurrence of a subsequent transformation may lead to
B-NHL.
A number of epidemiological studies regarding the
association between HCV infection and the occurrence of
B-NHL have been carried out [5, 7, 62–65]. A substantial
geographic as well as demographic variation exists in the
association between HCV infection and risk of B-NHL.
A positive association was found in Italy, Japan, and
USA. A recent case-control study with a large number of
subjects from the International Lymphoma Epidemiology
Consortium based in Europe, North America, and Australia
further conﬁrmed the association between HCV infection
and NHL and speciﬁc B-NHL subtypes, that is, diﬀuse large
B-cell lymphoma (DLBCL), marginal zone lymphoma, and
lymphoplasmacyticlymphoma[6].Incontrast,otherstudies
from Northern Europe, UK, and Canada failed to show the4 Advances in Hematology
association. Geographic diﬀerences in HCV genotype have
been thought to cause these discrepancies [66] although this
remains controversial. Large-scale, population-based, well-
controlled studies are necessary to reach a robust conclusion.
It can be concluded that, at least in areas with a high
prevalence of HCV carriage, HCV is an important risk factor
for B-cell lymphomagenesis.
In this paper, we propose a novel hypothesis that peri-
pheralBcellsserveasreservoirsforpersistentHCVinfection.
We also suggest that long-lasting HCV infection in B cells
may induce lymphoproliferative disorders that may eventu-
ally evolve into B-cell NHL, although little is known about
the mechanism responsible for B-cell lymphomagenesis. In
the remainder of this section, the possible mechanisms of
B-NHL tumorigenesis induced by HCV infection will be
discussed based on current knowledge of lymphomagenesis-
related genes.
Activation-induced cytidine deaminase(AID)isessential
for somatic hypermutation (SHM) and class switch re-
combination of immunoglobulin genes in B cells [67–69].
Recently, it has been proposed that AID may be instru-
mental in the initiation and progression of B-NHL. This is
because a malfunction in either of the two processes stated
above is apparently responsible for chromosomal transloca-
tions and aberrant SHM, which are the two main causes of
genetic lesions associated with B-NHL [70, 71]. Several
o n c o g e n e sh a v eb e e nd e m o n s t r a t e dt ob et a r g e t sf o rS H M
with immunoglobulin genes. In many cases, these anomalies
activate the DNA damage response system that either allows
DNA repair or eliminates the aberrant B-cell clones [72].
FailureoftheserepairsystemsmaybeacauseofB-cellmalig-
nancies. Speciﬁc features of SHM are the predominance of
single-based substitution, the preference for transitions over
transversion, and the speciﬁc targeting of the RGYW/WRCY
motif. Pasqualucci et al. showed that hypermutation of
proto-oncogenes exists in DLBCL [71]. However, in HCV-
associated NHL, the number of mutations in some proto-
oncogenes was lower than that already found in HCV-
negative B-cell NHL patients [73]. Because there is a close
association between HCV infection and the incidence of B-
NHL, as described above [6, 7], analyzing the expression
levels of AID in CHC B cells is of great interest.
Laietal.establishedaB-cellline(SB)fromHCV-infected
B-NHL cells. The virus particles produced from SB cell
culture could infect primary human hepatocytes, Raji cells,
and PBMC in vitro [74]. They examined the expression of
AID in Raji cells and PBMC after HCV infection in vitro.
It was found that HCV infection activated the expression
of AID in Raji cells. AID expression level was also higher
in PBMC of patients infected with HCV than in uninfected
individuals [75]. However, their study did not assess which
cell population showed an enhancement of AID expression.
It was observed in our recent study that expression levels
of AID mRNA were markedly enhanced in the CD19+,
but not in the CD19− subset of patients with CHC [32].
Furthermore, the enhanced expression of AID protein was
detected in the CD19+ B-cell subset of patients with CHC
[32]. The fact that this enhancement of AID expression is
conﬁned to the B-cell subset is extremely intriguing because
several reports have demonstrated the augmented expression
of AID in B-NHL [26, 76, 77].
Using an AID-deﬁcient mouse model, Pasqualucci et al.
concluded that AID is required for germinal center-derived
lymphomagenesis [78]. They addressed the issue of errors in
AID-mediated antigen receptor gene modiﬁcation processes
being the principal contributors to the pathogenesis of
human B-NHL. Increasing epidemiological evidence has
highlighted the close correlation between HCV infection and
B-NHL [6, 7, 79]. Thus, it is tempting to hypothesize that
the enhancement of AID in CHC B cells is at least partly
responsible for the initiation of lymphomagenesis. In fact,
several recent studies suggest that AID is deeply involved in
tumorigenesis[80–84].Notably,HCVenhancedAIDexpres-
sion by NF-κB activation through the expression of viral core
proteins. Furthermore, NF-κB expression was upregulated
and activated by HCV NS2 proteins in HepG2 cells [85].
These ﬁndings suggest that inappropriate expression of AID
acts as a DNA mutator that enhances genetic susceptibility to
mutagenesis [86].
Additionally, enhanced expression of other lymphoma-
genesis-related genes including cyclin D1, cyclin D2, BAL,
STK15, and galectin-3 in CHC B cells is worth considering
[32]. Overexpression of CCND1, which alters cell-cycle
progression, is frequently observed in various tumors
and may contribute to tumorigenesis [87, 88], whereas
CCND2 is known to be expressed at constitutively high
levels in B-NHL [89]. BAL is a novel risk-related gene in
DLBCL, a typical B-NHL [90], while STK15 is a gene highly
expressed in a histologically aggressive type of NHL [91].
Galectin-3 is an antiapoptotic protein, highly expressed in
DLBCL [92]. Presumably, the enhanced expression of these
genes in CHC B cells [32] may also correlate with B-cell
lymphomagenesis.
Tumor necrosis factor alpha-induced protein 3, also
called A20, was ﬁrst identiﬁed in 1990 as a TNF-induced
cytoplasmic protein with zinc ﬁnger motifs [93], which
thereafter has been described as a key player in the negative
regulation of inﬂammation by terminating NF-κB signaling
[94–96]. Recently, A20 has gained much attention as a novel
t u m o rs u p p r e s s o r[ 97, 98]. Honma et al. ﬁrst reported that
A20 is frequently inactivated or even deleted in mantle
cell lymphoma and DLBCL, and they raised the possibility
that inactivation of A20 may be at least partly responsible
for lymphomagenesis [99, 100]. Other investigators have
subsequently supported their ﬁndings [101, 102]. Moreover,
A20 also regulates antiviral signaling as well as programmed
cell death [103–105]. Currently, the expression, biological
activities, and mechanisms of action of A20 have been
the focus of attention on a wide scale [106]. Interestingly,
Ngueyn et al. reported [107] that the HCV core protein
induced an increased expression of A20 in the human
hepatocyte cell line HepG2, which has generated a genuine
interest in the expression of A20 in peripheral B cells of
patients with CHC. Our preliminary data suggests that the
A20moleculeispartiallycleavedinCHCBcells(Kusunokiet
al.; in preparation). An intriguing possibility is that the A20
gene interacts with and is mutated by AID, the expression
of which is dramatically enhanced in CHC B cells [32]. InAdvances in Hematology 5
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Figure 2: Role of HCV infection in B-cell lymphomagenesis, a
hypothesis.
this regard, the expression levels of A20 in patients with
B-NHL suﬀering from chronic HCV infection are worth
investigating.
5. Conclusion
In this paper, we summarized recent studies illuminating the
possible role of HCV infection in B-cell lymphomagenesis.
We proposed a hypothesis that HCV utilizes B cells as
reservoirs for persistent infection, which could result in the
enhancedexpressionoflymphomagenesis-relatedgenes,par-
ticularly AID, which is thought to be crucial for the initiation
and progression of B-NHL (Figure 2). Elimination of HCV
in plasma by antiviral reagents as well as in peripheral B
cells by speciﬁc antibodies would be beneﬁcial for patients
with CHC to achieve a complete viral clearance. Finally,
although a positive association between HCV infection and
B-NHL occurrence is still being debated [108–111], it is
worthwhile to investigate the possible mechanisms by which
B-cell lymphoproliferative disorders, which may evolve into
B-NHL, are induced in patients with CHC.
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